AR088244A1 - oxMIF COMO MARCADOR DE DIAGNOSTICO - Google Patents

oxMIF COMO MARCADOR DE DIAGNOSTICO

Info

Publication number
AR088244A1
AR088244A1 ARP120103713A ARP120103713A AR088244A1 AR 088244 A1 AR088244 A1 AR 088244A1 AR P120103713 A ARP120103713 A AR P120103713A AR P120103713 A ARP120103713 A AR P120103713A AR 088244 A1 AR088244 A1 AR 088244A1
Authority
AR
Argentina
Prior art keywords
oxmif
mif
refers
diagnostic
diagnostic marker
Prior art date
Application number
ARP120103713A
Other languages
English (en)
Spanish (es)
Inventor
Thiele Michael
Voelkel Dirk
Douillard Patrice
J Kerschbaumer Randolf
Scheiflinger Fritz
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of AR088244A1 publication Critical patent/AR088244A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
ARP120103713A 2011-10-07 2012-10-05 oxMIF COMO MARCADOR DE DIAGNOSTICO AR088244A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161545042P 2011-10-07 2011-10-07
US201261624943P 2012-04-16 2012-04-16
US201261668841P 2012-07-06 2012-07-06

Publications (1)

Publication Number Publication Date
AR088244A1 true AR088244A1 (es) 2014-05-21

Family

ID=46980957

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103713A AR088244A1 (es) 2011-10-07 2012-10-05 oxMIF COMO MARCADOR DE DIAGNOSTICO

Country Status (8)

Country Link
US (1) US9958456B2 (https=)
EP (1) EP2748613B1 (https=)
JP (1) JP2014530360A (https=)
AR (1) AR088244A1 (https=)
AU (1) AU2012320597C1 (https=)
HK (1) HK1198591A1 (https=)
TW (1) TW201321408A (https=)
WO (1) WO2013050453A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530360A (ja) 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
EP2872897B1 (en) * 2012-07-10 2017-10-18 Baxalta GmbH Anti-mif immunohistochemistry
US9536304B2 (en) * 2013-08-30 2017-01-03 Dairy Quality Inc. Determining pathogens based on an image of somatic cells in a fluid sample
EP3052943B1 (en) * 2013-10-04 2019-11-20 Cell Ideas Pty Ltd. Biomarkers for cell therapy
WO2015106973A2 (en) * 2014-01-03 2015-07-23 Baxter Healthcare S.A. Anti-mif immunohistochemistry
WO2016026956A1 (en) * 2014-08-22 2016-02-25 Baxalta GmbH Detection of cho-mif contaminations
EP3802595A1 (en) * 2018-06-07 2021-04-14 OncoOne Research & Development GmbH Anti-oxmif/anti-cd3 antibody for cancer treatment
JP2023504620A (ja) * 2019-12-06 2023-02-06 オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 抗ｏｘＭＩＦ／抗ＣＤ３二重特異性抗体構築物
AU2022218320A1 (en) * 2021-02-03 2023-07-27 Oncoone Research & Development Gmbh ANTI-oxMIF RADIOIMMUNOCONJUGATE

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299814A (en) 1979-05-25 1981-11-10 Monsanto Company Radioimmunoassay of MIF
JPH0672158B2 (ja) * 1984-05-24 1994-09-14 チバ−ガイギ− アクチエンゲゼルシヤフト 精製されたヒトマクロファージ遊走阻止因子
US4946674A (en) 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
US4708937A (en) 1984-10-15 1987-11-24 Brigham & Women's Hospital Purified migration inhibitory factor also having colony stimulating factor activity
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ES2052602T3 (es) 1986-10-03 1994-07-16 Ciba Geigy Ag Nuevos peptidos afines a las linfocinas.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0463037A1 (en) 1989-03-17 1992-01-02 Genetics Institute, Inc. Human macrophage migration inhibitory factor
US5785054A (en) 1989-06-06 1998-07-28 Kelly; Patrick D. Genital lubricant with zinc salt, labelled as anti-viral agent
GB8915414D0 (en) 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
CA2044590A1 (en) 1989-11-13 1991-05-14 Marc D. Better Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5227459A (en) 1990-05-18 1993-07-13 Yale University Synthetic melanin
US5786168A (en) 1990-06-04 1998-07-28 Kirin Beer Kabushiki Kaisha Method for recombinant production of antigen non-specific glycosylation inhibiting factor (GIF)
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US6774227B1 (en) 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
DE69435303D1 (de) 1993-05-17 2010-09-02 Cytokine Pharmasciences Inc Er behandlung von krankheiten bei denen eine cytok
US6645493B1 (en) 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
US5559028A (en) 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
EP0770086A4 (en) 1994-05-16 1998-07-15 Human Genome Sciences Inc MACROPHAGE MIGRATION INHIBITING FACTOR-3
US5747023A (en) 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
SI9400363A (en) 1994-09-19 1996-08-31 Mozetic Francky Bojana Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein
WO1996015242A2 (en) 1994-11-16 1996-05-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor
JPH0977799A (ja) 1995-09-13 1997-03-25 Sapporo Immuno Diagnostic Lab:Kk ヒト−マクロファージ遊走阻止因子（ヒト−ｍｉｆ）に対するモノクローナル抗体および該抗体を産生するハイブリドーマ
AU1087797A (en) 1996-01-03 1997-08-01 Australian National University, The Clip analogues and autoimmune disease
US6420188B1 (en) 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US5726020A (en) 1996-06-11 1998-03-10 University Of Massachusetts Inhibition of II synthesis
US6297253B1 (en) 1996-10-15 2001-10-02 The Picower Institute For Medical Research Compounds and methods of use to treat infectious diseases
AU6336398A (en) 1997-02-24 1998-09-09 Johns Hopkins University, The Immunomodulatory polypeptides derived from the invariant chain of mhc class ii
ES2248898T3 (es) 1997-05-02 2006-03-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Inmunotoxinas que comprenden una proteina onc dirigida contra celulas malignas.
CA2205680A1 (en) 1997-05-16 1998-11-16 The University Of Western Ontario Clip immunomodulatory peptide
US6011005A (en) 1997-09-18 2000-01-04 The Picower Institute For Medical Research Prevention of pregnancy miscarriages
PT1028738E (pt) 1997-11-05 2003-08-29 Univ Southern California Utilizacao de citoquinas e mitogenios para inibir respostas imunitarias patologicas
HU229520B1 (en) 1999-02-12 2014-01-28 Scripps Research Inst Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
WO2001032606A1 (en) 1999-10-29 2001-05-10 The Picower Institute For Medical Research Compounds having mif antagonist activity
US6268151B1 (en) 2000-01-20 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of macrophage migration inhibitory factor expression
WO2001064749A2 (en) * 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
WO2002079517A1 (en) 2001-03-29 2002-10-10 Cytokine Pharmasciences, Inc. Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
US7205107B2 (en) 2001-12-21 2007-04-17 Cytokine Pharmasciences, Inc. Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease
US20050202010A1 (en) 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
US8883160B2 (en) 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
CN101374546B (zh) 2005-12-16 2016-03-23 Ibc医药公司 基于免疫球蛋白的多价生物活性装配体
CN100457895C (zh) 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
KR20160105943A (ko) 2008-01-04 2016-09-07 백스터 인터내셔널 인코포레이티드 항 ｍｉｆ 항체
EP2079202A1 (en) * 2008-01-08 2009-07-15 NEC Corporation Method for optimizing the triggering of the transmission of buffer status reporting (BSR) information
WO2011090492A1 (en) 2010-01-19 2011-07-28 Immunomedics, Inc. Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
WO2013050457A1 (en) 2011-10-07 2013-04-11 Baxter Healthcare S.A. Characterization of cho-mif gene and protein, and use thereof
JP2014530360A (ja) 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ

Also Published As

Publication number Publication date
AU2012320597C1 (en) 2015-10-15
HK1198591A1 (en) 2015-04-30
EP2748613A1 (en) 2014-07-02
US20140248638A1 (en) 2014-09-04
WO2013050453A1 (en) 2013-04-11
WO2013050453A4 (en) 2013-06-06
JP2014530360A (ja) 2014-11-17
AU2012320597A1 (en) 2013-05-09
TW201321408A (zh) 2013-06-01
AU2012320597B2 (en) 2015-05-21
US9958456B2 (en) 2018-05-01
EP2748613B1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
AR088244A1 (es) oxMIF COMO MARCADOR DE DIAGNOSTICO
MX367366B (es) Composiciones y metodos para diagnosticar tumores de tiroides.
NI201200014A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina - 2 humana
AR092818A1 (es) Anticuerpo tau humanizado
BR112013010952A2 (pt) sistemas de rmn e métodos para a detecção rápida de analisados
MX347853B (es) Ensayo cuantitativo rapido para medir la funcion del regulador de conductancia de transmembrana de fibrosis quistica (cftr) en un molde de cultivo intestinal primario.
AR092779A1 (es) Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau
CR20110470A (es) Proteínas de union a il-17
MX362514B (es) Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
BR112015022821A2 (pt) método para avaliar status renal em um indivíduo e kit de ensaio de diagnóstico
WO2014165536A8 (en) Methods and kits for the diagnosis of influenza
ECSP099547A (es) Anticuerpos neutralizantes del citomegalovirus humano y su uso
BRPI0807318B8 (pt) "microrna associado a exossomos como marcador diagnóstico"
AR063493A1 (es) Nuevos anticuerpos anti notch 3 y su uso para la deteccion y el diagnostico de enfermedades
ECSP13013092A (es) Ensayo de lisiloxidasa-homólogo 2 y métodos de uso del mismo
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
MX2012002909A (es) Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
MX343873B (es) Ensayo de diagnostico de anticuerpo.
BR112013031431A2 (pt) método para o diagnóstico da doença de gaucher
BR112013007041A2 (pt) animal não humano, descendente, linhagem de células, tecido, explante de órgão, ou cultura dos mesmos, uso do modelo de doenças inflamatórias e métodos para o rastreio de compostos anti-inflamatórios e para a avaliação
BR112017006215A2 (pt) método para detectar uma proximidade espacial de um primeiro e um segundo epítopos, método para estratificação de um indivíduo, kit para realizar o método, e, uso do kit
WO2014169011A3 (en) Methods for treating immune diseases
BR112015027249A2 (pt) método de diagnóstico de câncer

Legal Events

Date Code Title Description
FB Suspension of granting procedure